Detection of epstein-barr virus DNA in serum or plasma for nasopharyngeal cancer: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 7-8, 2011, Pages 495-502

  Liu, Yu ^a   Fang, Zhijia ^b   Liu, Li ^c   Yang, Shujuan ^a   Zhang, Lishi ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; BLOOD ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DNA DETERMINATION; EPSTEIN BARR VIRUS; HUMAN; META ANALYSIS; NASOPHARYNX CANCER; SENSITIVITY AND SPECIFICITY;

DNA, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; PLASMA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMAN HERPESVIRUS 4;

EID: 79960450469     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0012     Document Type: Article

References (41)

1. Busson P, Keryer C, Ooka T, et al. (2004) EBV-associated naso-pharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 12:356-360. (Pubitemid 38987821)
2. Chan AT, Lo YM, Zee B, et al. (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferen-tiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614-1619. (Pubitemid 35378726)
3. Chan KC, Lo YM. (2002) Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 12:489-496. (Pubitemid 35370761)
4. Chan KH, Gu YL, Ng F, et al. (2003) EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopha-ryngeal carcinoma. Int J Cancer 105:706-709. (Pubitemid 36687741)
5. Chang KP, Hsu CL, Chang YL, et al. (2008) Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 44:784-792.
6. Fachiroh J, Schouten T, Hariwiyanto B, et al. (2004) Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190:53-62. (Pubitemid 38858404)
7. Fan H, Nicholls J, Chua D, et al. (2004) Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 112:1036-1041. (Pubitemid 39507011)
8. Fan H, Schichman SA, Swinnen LJ, et al. (2001) Analytic validation of a competitive polymerase chain reaction assay for measuring Epstein-Barr viral load. Diagn Mol Pathol 10: 255-264. (Pubitemid 33123935)
9. Fournie GJ, Courtin JP, Laval F, et al. (1995) Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 91:221-227.
10. Henle G, Henle W. (1976) Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17:1-7.
11. Karray H, Ayadi W, Fki L, et al. (2005) Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 75:593-602. (Pubitemid 40293528)
12. Krishna SM, James S, Kattoor J, et al. (2004) Serum EBV DNA as a biomarker in primary nasopharyngeal carcinoma of Indian origin. Jpn J Clin Oncol 34:307-311. (Pubitemid 43115311)
13. Lee TH, Montalvo L, Chrebtow V, et al. (2001) Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41:276-282. (Pubitemid 32220522)
14. Leung SF, Tam JS, Chan AT, et al. (2004) Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 50:339-345. (Pubitemid 38156375)
15. Levine PH, Connelly RR, Milman G, et al. (1988) Epstein-Barr virus serology in the control of nasopharyngeal carcinoma. Cancer Detect Prev 12:357-362.
16. Lijmer JG, Mol BW, Heisterkamp S, et al. (1999) Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282:1061-1066. (Pubitemid 29436454)
17. Lin JC, Chen KY, Wang WY, et al. (2001) Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol 19:2607-2615. (Pubitemid 32441365)
18. Lo YM. (2001) Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopha-ryngeal carcinoma. Biomed Pharmacother 55:362-365. (Pubitemid 32900535)
19. Lo YM, Chan AT, Chan LY, et al. (2000) Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60:6878-6881. (Pubitemid 32059157)
20. Lo YM, Chan LY, Lo KW, et al. (1999) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59:1188-1191. (Pubitemid 29136244)
21. Low WK, Leong JL, Goh YH, et al. (2000) Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 123:505-507.
22. Mai S, Zong Y, Zhang M, et al. (2002) Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J (Engl) 115:1895-1897. (Pubitemid 36105076)
23. Mo WN, Tang AZ, Zhou L, et al. (2009) Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+T cells in patients with nasopha-ryngeal carcinomas positive for IgA antibody to EBV viral capsid antigen. Chin Med J (Engl) 122:1173-1178.
24. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. (1998) Epstein-Barr viral DNA in serum of patients with na-sopharyngeal carcinoma. Clin Cancer Res 4:665-669. (Pubitemid 28193566)
25. Ng WT, Yau TK, Yung RW, et al. (2005) Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 113:998-1001. (Pubitemid 40096880)
26. O TM, Yu G, Hu K, et al. (2007) Plasma Epstein-Barr virus im-munoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States. Otolaryngol Head Neck Surg 136:992-997. (Pubitemid 46844851)
27. Ozyar E, Gultekin M, Alp A, et al. (2007) Use of plasma Ep-stein-Barr virus DNA monitoring as a tumor marker in follow-up of patients with nasopharyngeal carcinoma: preliminary results and report of two cases. Int J Biol Markers 22:194-199. (Pubitemid 350081628)
28. Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
29. Pratesi C, Bortolin MT, D'Andrea M, et al. (2003) Quantitative plasma/serum EBV DNA load by LMP2A determination in an Italian cohort of NPC patients. J Clin Virol 28:155-164. (Pubitemid 37040867)
30. Raab-Traub N. (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12:431-441. (Pubitemid 35370756)
31. Shao JY, Li YH, Gao HY, et al. (2004a) Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immu-noglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 100:1162-1170.
32. Shao JY, Zhang Y, Li YH, et al. (2004b) Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res 24:4059-4066. (Pubitemid 40468707)
33. Shotelersuk K, Khorprasert C, Sakdikul S, et al. (2000) Epstein-Barr virus DNA in serum/plasma as a tumor marker for na-sopharyngeal cancer. Clin Cancer Res 6:1046-1051. (Pubitemid 30159366)
34. Smidt N, Rutjes AW, van der Windt DA, et al. (2006) Reprodu-cibility of the STARD checklist: an instrument to assess the quality of reporting of diagnostic accuracy studies. BMC Med Res Methodol 6:12.
35. Stevens SJ, Pronk I, Middeldorp JM. (2001) Toward standardization of Epstein-Barr virus DNA load monitoring: un-fractionated whole blood as preferred clinical specimen. J Clin Microbiol 39:1211-1216. (Pubitemid 32275408)
36. Tao Q, Chan AT. (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9:1-24. (Pubitemid 47398642)
37. Tao Q, Young LS, Woodman CB, et al. (2006) Epstein-Barr virus (EBV) and its associated human cancers\genetics, epigenet-ics, pathobiology and novel therapeutics. Front Biosci 11:2672-2713. (Pubitemid 43806572)
38. Wei WI, Sham JS. (2005) Nasopharyngeal carcinoma. Lancet 365:2041-2054. (Pubitemid 40812341)
39. Yang X, Goldstein AM, Chen CJ, et al. (2006) Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer 118:780-784. (Pubitemid 43076031)
40. Yang XR, Diehl S, Pfeiffer R, et al. (2005) Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopha-ryngeal carcinoma families in Taiwan. Cancer Epidemiol Biomarkers Prev 14:900-905. (Pubitemid 40478554)
41. Zhang Y, Gao HY, Feng HX, et al. (2004) Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi 84:982-986.